LifeVantage completes study of MB System on activating GLP-1 production

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the MindBody GLP-1 System known as the MB System on activating GLP-1 production. The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation. Key genes involved in the production and regulation of GLP-1 and associated neuropeptides were thoroughly examined, including: GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis. “The completion of this trial and the positive results we’re starting to see with this international formula affirm our success in activating the body’s own production of the GLP-1 hormone,” says Lisa Barnes, VP of R&D and Regulatory at LifeVantage. “We’re excited to bring the MB System(TM) to our international audience starting in March and provide them with the same life-changing results that have already transformed the health of so many